These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 17083020)

  • 1. Issues related to the design and interpretation of clinical trials of salvage therapy for invasive mold infection.
    Almyroudis NG; Kontoyiannis DP; Sepkowitz KA; DePauw BE; Walsh TJ; Segal BH
    Clin Infect Dis; 2006 Dec; 43(11):1449-55. PubMed ID: 17083020
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Salvage therapy trials in invasive fungal disease: challenges and opportunities.
    Powers JH
    Clin Infect Dis; 2006 Dec; 43(11):1456-60. PubMed ID: 17083021
    [No Abstract]   [Full Text] [Related]  

  • 3. Improved outcomes associated with advances in therapy for invasive fungal infections in immunocompromised hosts.
    Metcalf SC; Dockrell DH
    J Infect; 2007 Oct; 55(4):287-99. PubMed ID: 17697716
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevention and early treatment of invasive fungal infection in patients with cancer and neutropenia and in stem cell transplant recipients in the era of newer broad-spectrum antifungal agents and diagnostic adjuncts.
    Segal BH; Almyroudis NG; Battiwalla M; Herbrecht R; Perfect JR; Walsh TJ; Wingard JR
    Clin Infect Dis; 2007 Feb; 44(3):402-9. PubMed ID: 17205448
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Salvage therapy for invasive aspergillosis.
    Dockrell DH
    J Antimicrob Chemother; 2008 Jan; 61 Suppl 1():i41-4. PubMed ID: 18063604
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Forum report: issues in the evaluation of diagnostic tests, use of historical controls, and merits of the current multicenter collaborative groups.
    Bennett JE; Kauffman C; Walsh T; de Pauw B; Dismukes W; Galgiani J; Glauser M; Herbrecht R; Lee J; Pappas P; Powers J; Rex J; Verweij P; Viscoli C
    Clin Infect Dis; 2003 Apr; 36(Suppl 3):S123-7. PubMed ID: 12679896
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Considerations in clinical trials of combination antifungal therapy.
    Powers JH
    Clin Infect Dis; 2004 Oct; 39 Suppl 4():S228-35. PubMed ID: 15546123
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Empirical antifungal treatment: a valid alternative for invasive fungal infection.
    Vallejo C; Barberán J
    Rev Esp Quimioter; 2011 Sep; 24(3):117-22. PubMed ID: 21947092
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical practice: combination antifungal therapy for mold infections: much ado about nothing?
    Vazquez JA
    Clin Infect Dis; 2008 Jun; 46(12):1889-901. PubMed ID: 18466092
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phaeohyphomycosis in a tertiary care cancer center.
    Ben-Ami R; Lewis RE; Raad II; Kontoyiannis DP
    Clin Infect Dis; 2009 Apr; 48(8):1033-41. PubMed ID: 19267655
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design of efficacy trials of cytokines in combination with antifungal drugs.
    Kullberg BJ; Oude Lashof AM; Netea MG
    Clin Infect Dis; 2004 Oct; 39 Suppl 4():S218-23. PubMed ID: 15546121
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Issues in clinical trials of prophylaxis of fungal infections.
    Powers JH
    Clin Infect Dis; 2004 Oct; 39 Suppl 4():S211-7. PubMed ID: 15546120
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Counterpoint: alternative trial designs for antifungal drugs--time to talk.
    Powers JH
    Clin Infect Dis; 2001 Jul; 33(1):107-9. PubMed ID: 11389502
    [No Abstract]   [Full Text] [Related]  

  • 14. When primary antifungal therapy fails.
    Nucci M; Perfect JR
    Clin Infect Dis; 2008 May; 46(9):1426-33. PubMed ID: 18419447
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early diagnosis of fungal infection in immunocompromised patients.
    Barnes RA
    J Antimicrob Chemother; 2008 Jan; 61 Suppl 1():i3-6. PubMed ID: 18063601
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sequential prescription of antifungals in invasive fungal infection: the importance of mechanism of action.
    Candel FJ; Matesanz M; Mensa J
    Int J Antimicrob Agents; 2008 Nov; 32 Suppl 2():S133-5. PubMed ID: 19013337
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The design of clinical trials that evaluate antifungal prophylaxis and combination therapy: introduction and overview.
    Rex JH; Wingard JR; Wenzel R; Herbrecht R; Sobel J; Edwards JE
    Clin Infect Dis; 2004 Oct; 39 Suppl 4():S165-9. PubMed ID: 15546112
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Salvage therapy for aspergillosis.
    Bennett JE
    Clin Infect Dis; 2005 Sep; 41 Suppl 6():S387-8. PubMed ID: 16108004
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Amphotericin B lipid complex versus liposomal amphotericin B monotherapy for invasive aspergillosis in patients with hematologic malignancy.
    Hachem RY; Boktour MR; Hanna HA; Husni RN; Torres HA; Afif C; Kontoyiannis DP; Raad II
    Cancer; 2008 Mar; 112(6):1282-7. PubMed ID: 18224662
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluating prophylaxis of invasive fungal infections in patients with haematologic malignancies.
    Maertens J
    Eur J Haematol; 2007 Apr; 78(4):275-82. PubMed ID: 17241370
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.